Private Advisory Group LLC bought a new stake in STAAR Surgical (NASDAQ:STAA) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 23,453 shares of the medical instruments supplier’s stock, valued at approximately $1,007,000. Private Advisory Group LLC owned 0.05% of STAAR Surgical as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also made changes to their positions in STAA. Chicago Equity Partners LLC bought a new stake in STAAR Surgical during the second quarter worth about $1,423,000. Sei Investments Co. bought a new stake in STAAR Surgical during the second quarter worth about $910,000. Tower Research Capital LLC TRC lifted its position in STAAR Surgical by 367.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,877 shares of the medical instruments supplier’s stock worth $213,000 after purchasing an additional 5,405 shares during the period. American Century Companies Inc. lifted its position in STAAR Surgical by 131.2% during the second quarter. American Century Companies Inc. now owns 78,031 shares of the medical instruments supplier’s stock worth $2,419,000 after purchasing an additional 44,284 shares during the period. Finally, Strs Ohio lifted its position in STAAR Surgical by 26.7% during the second quarter. Strs Ohio now owns 34,600 shares of the medical instruments supplier’s stock worth $1,072,000 after purchasing an additional 7,300 shares during the period. 80.20% of the stock is owned by institutional investors.
Shares of NASDAQ STAA opened at $43.45 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.35 and a quick ratio of 4.76. The stock has a market cap of $1.90 billion, a price-to-earnings ratio of 4,345.00 and a beta of 2.05. STAAR Surgical has a 12 month low of $13.60 and a 12 month high of $54.00.
Several equities research analysts recently weighed in on STAA shares. BidaskClub cut shares of STAAR Surgical from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 31st. Canaccord Genuity reissued a “buy” rating and set a $43.00 target price (up previously from $32.00) on shares of STAAR Surgical in a research note on Thursday, August 2nd. Benchmark initiated coverage on STAAR Surgical in a research note on Monday, August 6th. They set a “buy” rating and a $45.00 target price for the company. Finally, Zacks Investment Research raised STAAR Surgical from a “hold” rating to a “strong-buy” rating and set a $46.00 target price for the company in a research note on Thursday, August 9th. Four analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company’s stock. STAAR Surgical has an average rating of “Buy” and an average price target of $45.25.
In other STAAR Surgical news, Director William P. Wall sold 5,000 shares of the business’s stock in a transaction dated Monday, August 20th. The stock was sold at an average price of $41.35, for a total transaction of $206,750.00. Following the completion of the transaction, the director now owns 16,235 shares of the company’s stock, valued at $671,317.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 3.90% of the stock is currently owned by insiders.
WARNING: This report was reported by Week Herald and is the property of of Week Herald. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://weekherald.com/2018/11/14/private-advisory-group-llc-invests-1-01-million-in-staar-surgical-staa.html.
STAAR Surgical Company Profile
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.
See Also: NASDAQ Stock Market Explained
Want to see what other hedge funds are holding STAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STAAR Surgical (NASDAQ:STAA).
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.